» Articles » PMID: 36845345

Surgical Margin Assessment of Bone Tumours: A Systematic Review of Current and Emerging Technologies

Overview
Journal J Bone Oncol
Publisher Elsevier
Date 2023 Feb 27
PMID 36845345
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma is the most common malignant tumour of the bone. Complete surgical excision is critical to achieve optimal outcomes and lower recurrence rates. However, accurate assessment of tumour margins remains a challenge and multiple technologies are employed for this purpose. The aim of this study is to highlight current and emerging technologies and their efficacy in detecting clear bone margins intraoperatively, through a systematic review of the literature. The following databases were searched using the OVID platform: Medline, Embase, Global Health and Google Scholar. Studies were screened using predetermined eligibility criteria. Data was extracted based on study and patient characteristics, modes of detection, and commercial availability, followed by quality assessment. A total of 17 studies were included. The primary diagnosis varied, with osteosarcoma being reported by 9 studies. Three studies reported relapse, ranging between 17.6%-48%. Twelve studies reported non-invasive imaging as the mode of detection used, while 4 studies reported the use of frozen section. MRI and CT were found to have an accuracy of up to 93 %. Raman spectroscopy was reported to have an accuracy, sensitivity, and specificity of 69%, 58.8% and 83.3% respectively. CT had a sensitivity and specificity up to 83% and 100%, respectively. In conclusion, there seems to be high potential for the use of multimodal technologies to increase the accuracy of intraoperative margin assessment. Although imaging modalities possess a fair level of accuracy, they carry the risk of radiation exposure, are expensive, and cannot be used in-situ. Future clinical trials are needed to test the effectiveness of these technologies to measure the diagnostic accuracy and overall patient survival.

Citing Articles

Malignant Bone and Soft Tissue Lesions of the Foot.

Angelini A, Biz C, Cerchiaro M, Longhi V, Ruggieri P J Clin Med. 2023; 12(8).

PMID: 37109375 PMC: 10146676. DOI: 10.3390/jcm12083038.

References
1.
Mutsaers A, Walkley C . Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells?. Bone. 2014; 62:56-63. DOI: 10.1016/j.bone.2014.02.003. View

2.
Houssami N, Morrow M . Margins in breast conservation: a clinician's perspective and what the literature tells us. J Surg Oncol. 2014; 110(1):2-7. DOI: 10.1002/jso.23594. View

3.
Boufettal M, Haddam A, Lalya I, El Zanati R, Mahfoud M, El Bardouni A . [Place of intraoperative isotopic markers in the management of osteoid osteoma]. Pan Afr Med J. 2015; 19:158. PMC: 4345215. DOI: 10.11604/pamj.2014.19.158.4919. View

4.
Brown H, Schiavone K, Gouin F, Heymann M, Heymann D . Biology of Bone Sarcomas and New Therapeutic Developments. Calcif Tissue Int. 2017; 102(2):174-195. PMC: 5805807. DOI: 10.1007/s00223-017-0372-2. View

5.
Bajpai J, Gamanagatti S, Sharma M, Kumar R, Vishnubhatla S, Khan S . Noninvasive imaging surrogate of angiogenesis in osteosarcoma. Pediatr Blood Cancer. 2009; 54(4):526-31. DOI: 10.1002/pbc.22328. View